Pawel Muranski

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Essentials of Th17 cell commitment and plasticity
    Pawel Muranski
    Hematology Branch, National Heart, Lung and Blood Institute, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 121:2402-14. 2013
  2. pmc Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?
    Pawel Muranski
    Clinical Research Center, National Institutes of Health, Room 3 5762, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 3:668-81. 2006
  3. pmc Tumor-specific Th17-polarized cells eradicate large established melanoma
    Pawel Muranski
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, Bethesda, MD 20892, USA
    Blood 112:362-73. 2008
  4. pmc Adoptive immunotherapy of cancer using CD4(+) T cells
    Pawel Muranski
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Curr Opin Immunol 21:200-8. 2009
  5. pmc Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells
    Claudia Wrzesinski
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 33:1-7. 2010
  6. pmc Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells
    Christopher A Klebanoff
    Clinical Investigator Development Program and 2 Experimental Transplantation and Immunology Branch, 3 Center for Cancer Research, National Cancer Institute, National Institutes of Health NIH, Bethesda, MD 20892
    J Exp Med 210:1961-76. 2013
  7. pmc Th17 cells are long lived and retain a stem cell-like molecular signature
    Pawel Muranski
    National Cancer Institute, Bethesda, MD 20892, USA
    Immunity 35:972-85. 2011
  8. pmc Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers
    Andrea Boni
    Clinical Research Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:4746-54. 2008
  9. pmc Type 17 CD8+ T cells display enhanced antitumor immunity
    Christian S Hinrichs
    National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Blood 114:596-9. 2009
  10. pmc Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Res 70:6725-34. 2010

Detail Information

Publications20

  1. pmc Essentials of Th17 cell commitment and plasticity
    Pawel Muranski
    Hematology Branch, National Heart, Lung and Blood Institute, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 121:2402-14. 2013
    ....
  2. pmc Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?
    Pawel Muranski
    Clinical Research Center, National Institutes of Health, Room 3 5762, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 3:668-81. 2006
    ..We also address safety issues associated with translating experimental animal results of total lymphoid ablation into clinical practice...
  3. pmc Tumor-specific Th17-polarized cells eradicate large established melanoma
    Pawel Muranski
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, Bethesda, MD 20892, USA
    Blood 112:362-73. 2008
    ..This principle should be considered in designing clinical trials involving adoptive transfer-based immunotherapy of human malignancies...
  4. pmc Adoptive immunotherapy of cancer using CD4(+) T cells
    Pawel Muranski
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Curr Opin Immunol 21:200-8. 2009
    ....
  5. pmc Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells
    Claudia Wrzesinski
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 33:1-7. 2010
    ..Thus, increased intensity lymphodepletion triggers enhanced tumor treatment efficacy and the benefits of high-dose total body irradiation must be titrated against its risks...
  6. pmc Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells
    Christopher A Klebanoff
    Clinical Investigator Development Program and 2 Experimental Transplantation and Immunology Branch, 3 Center for Cancer Research, National Cancer Institute, National Institutes of Health NIH, Bethesda, MD 20892
    J Exp Med 210:1961-76. 2013
    ..These findings establish a critical role for RA in regulating the homeostasis of pre-DC-derived DC subsets and have implications for the management of patients with immune deficiencies resulting from malnutrition and irradiation. ..
  7. pmc Th17 cells are long lived and retain a stem cell-like molecular signature
    Pawel Muranski
    National Cancer Institute, Bethesda, MD 20892, USA
    Immunity 35:972-85. 2011
    ..Thus, Th17 cells are not always short lived and are a less-differentiated subset capable of superior persistence and functionality...
  8. pmc Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers
    Andrea Boni
    Clinical Research Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:4746-54. 2008
    ..Taken together, these data indicate that the use of tumor-specific allogeneic CD8(+) T cells or CD4(+) can result in significant antitumor effects in the absence of measurable GVHD...
  9. pmc Type 17 CD8+ T cells display enhanced antitumor immunity
    Christian S Hinrichs
    National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Blood 114:596-9. 2009
    ..This report is the first description of a cancer therapy with IL-17-secreting CD8(+) T cells. These findings have implications for the improvement of CD8(+) T cell-based adoptive immunotherapy...
  10. pmc Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Res 70:6725-34. 2010
    ..Our findings reveal an approach to genetically modify T cells to reduce the cell number needed, eliminate the need for vaccines or systemic IL-2, and improve immunotherapy efficacy based on adoptive transfer of gene-engineered T cells...
  11. pmc Toll-like receptors in tumor immunotherapy
    Chrystal M Paulos
    National Cancer Institute, NIH, Mark O Hatfield Clinical Research Center, Bethesda, Maryland 20892 1502, USA
    Clin Cancer Res 13:5280-9. 2007
    ..We also discuss alternate regimens to chemotherapy or TBI, which might be used to safely treat patients with advanced disease and promote tumor regression...
  12. pmc Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity
    Christian S Hinrichs
    National Cancer Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:17469-74. 2009
    ..These results indicate that insertion of genes that confer antitumor specificity into naïve rather than central memory CD8(+) T cells may allow superior efficacy upon adoptive transfer...
  13. pmc Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice
    Christopher A Klebanoff
    Center for Cancer Research CCR, National Cancer Institute NCI, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:5343-52. 2011
    ..However, the relative contributions of each these individual components to the magnitude of the antitumor response have yet to be quantified...
  14. pmc Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 15:808-13. 2009
    ..These findings reveal a key role for Wnt signaling in the maintenance of 'stemness' in mature memory CD8(+) T cells and have major implications for the design of new vaccination strategies and adoptive immunotherapies...
  15. pmc Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells
    Yun Ji
    Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Immunol 12:1230-7. 2011
    ..Our findings identify the Blimp-1-Id3-E2A axis as a key molecular switch that determines whether effector CD8(+) T cells are programmed to die or enter the memory pool...
  16. pmc Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
    Christian S Hinrichs
    National Cancer Institute, Bethesda, MD, USA
    Blood 117:808-14. 2011
    ..Thus, these data suggest that naive cells resist terminal differentiation, or "exhaustion," maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy...
  17. pmc Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies
    Sid P Kerkar
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 34:343-52. 2011
    ..These results indicate that preclinical murine models of adoptive immunotherapies are more practical using γ-retroviral rather than lentiviral vectors...
  18. pmc IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 121:4746-57. 2011
    ....
  19. pmc Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling
    Chrystal M Paulos
    National Cancer Institute NCI, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 117:2197-204. 2007
    ..Thus, disruption of the homeostatic balance between the host and microbes can enhance cell-based tumor immunotherapy...
  20. pmc BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis
    Rahul Roychoudhuri
    Center for Cancer Research, National Cancer Institute, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    Nature 498:506-10. 2013
    ..These findings identify BACH2 as a key regulator of CD4(+) T-cell differentiation that prevents inflammatory disease by controlling the balance between tolerance and immunity. ..